title: Leukostasis Retinopathy: A New Clinical Manifestation of Chronic Myeloid Leukemia With Severe Hyperleukocytosis.
abstract: The authors report a new clinical manifestation of chronic myeloid leukemia. A 41-year-old man presented with significant visual loss, leading to a diagnosis of chronic myeloid leukemia. His white blood count exceeded that of any previously reported case of the disease with documented retinal findings (562,000/mm(3)), and clinical evaluation revealed the blockage of temporal retinal vessels by white blood cells. Hematologic findings resolved within 1 month of chemotherapy with dasatinib, and further treatment with intravitreal anti-VEGF agents resulted in the complete resolution of fundus findings. The authors propose that leukostasis retinopathy be recognized as a clinical manifestation of this life-threatening disease.
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Awh
authors.forename: John B
authors.initials: JB
authors.lastname: Miller
authors.forename: David M
authors.initials: DM
authors.lastname: Wu
authors.forename: Dean
authors.initials: D
authors.lastname: Eliott
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D000069439:Dasatinib / Q000627:therapeutic use; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy; D007958:Leukocyte Count; D007964:Leukocytosis / Q000175:diagnosis* / Q000188:drug therapy; D018921:Leukostasis / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D016133:Polymerase Chain Reaction; D012164:Retinal Diseases / Q000175:diagnosis* / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069439:Dasatinib